Aldose reductase and protein tyrosine phosphatase 1B inhibitory active compounds from Syzygium cumini seeds

Pharmaceutical Biology

Volumn 53, Issue 8, 2015, Pages 1176-1182

  Sawant, Laxman ^a   Singh, Vineet Kumar ^a   Dethe, Shekhar ^a   Bhaskar, Anirban ^a   Balachandran, Jaya ^a   Mundkinajeddu, Deepak ^a   Agarwal, Amit ^a  

^a Natural Remedies Pvt Ltd   (India)

Author keywords

Aldose reductase; Bioassay guided fractionation; Protein tyrosine phosphatase 1B; Rubuphenol; Syzygium cumini; Valoneic acid dilactone

Indexed keywords

5 (HYDROXYMETHYL) FURFURAL; ALDEHYDE REDUCTASE; ANTIDIABETIC AGENT; BAKUCHIOL; ELLAGIC ACID; GALLIC ACID; MASLINIC ACID; PROTEIN TYROSINE PHOSPHATASE 1B; QUERCETIN; RUBUPHENOL; SYZYGIUM CUMINI EXTRACT; UNCLASSIFIED DRUG; VALONEIC ACID DILACTONE; PLANT EXTRACT; PTPN1 PROTEIN, RAT;

ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ASSAY; IN VITRO STUDY; NONHUMAN; PLANT SEED; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ISOLATION AND PURIFICATION; MALE; METABOLISM; SYZYGIUM; WISTAR RAT;

MYRTACEAE; SYZYGIUM CUMINI;

ALDEHYDE REDUCTASE; ANIMALS; MALE; PLANT EXTRACTS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 1; RATS; RATS, WISTAR; SEEDS; SYZYGIUM;

EID: 84930801572     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.967784     Document Type: Article

References (37)

1. Aher AN, Pal SC, Yadav SK, et al. (2010). Isolation and characterization of phytoconstituents from Casuarina equisetifolia (Casuarinaceae). Asian J Chem 22:3429-34.
2. Aqil F, Gupta A, Munagala R, et al. (2012). Antioxidant and antiproliferative activities of anthocyanin/ellagitannin-enriched extracts from Syzygium cumini L. (Jamun, the Indian Blackberry). Nutr Cancer 64:428-38.
3. Arun R, Prakash MVD, Abraham SK, Premkumar K. (2011). Role of Syzygium cumini seed extract in the chemoprevention of in vivo genomic damage and oxidative stress. J Ethnopharmacol 134:329-33.
4. Ayyanar M, Babu PS, Ignacimuthu S. (2013). Syzygium cumini (L.) Skeels, a novel therapeutic agent for diabetes: Folk medicinal and pharmacological evidences. Complement Ther Med 2:232-43.
5. Ayyanar M, Babu PS. (2012). Syzygium cumini (L.) Skeels: A review of its phytochemical constituents and traditional uses. Asian Pac J Trop Biomed 2:240-6.
6. Baliga MS, Fernandes S, Thilakchand KR, et al. (2013). Scientific validation of the antidiabetic effects of Syzygium jambolanum DC (black plum), a traditional medicinal plant of India. J Altern Complement Med 19:191-7.
7. Banerjee J, Narendhirakannan RT. (2011). Phytochemical analyses, antibacterial, in vitro antioxidant and cytotoxic activities of ethanolic extract of Syzygium cumini (L.) seed extract. Int J Pharm Sci Res 2: 1799-806.
8. Barakat HH, Hussein SAM, Marzouk MS, et al. (1997). Polyphenolic metabolites of Epilobium hirsutum. Phytochemistry 46:935-41.
9. Bhuyan ZA, Rokeya B, Masum N, et al. (2010). Antidiabetic effect of Syzygium cumini L. seed on Type 2 diabetic rats. Dhaka Univ J Biol Sci 19:157-64.
10. Bona DKS, Bonfanti G, Bitencourt PE, et al. (2014). Syzygium cumini is more effective in preventing the increase of erythrocytic ADA activity than phenolic compounds under hyperglycemic conditions in vitro. J Physiol Biochem 70:321-30.
11. Brito FA, Lima LA, Ramos MFS, et al. (2007). Pharmacological study of anti-allergic activity of Syzygium cumini (L.) Skeels. Braz J Med Biol Res 40:105-15.
12. Burke Jr TR, Ye B, Yan X, et al. (1996). Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry 35:15989-96.
13. Chaudhary B, Mukhopadhyay K. (2012). Syzygium cumini (L.) Skeels: A potential source of nutraceuticals. Int J Pharm Bio Sci 2:46-53.
14. Cui CB, Zhao QC, Cai B, et al. (2002). Two new and four known polyphenolics obtained as new cell-cycle inhibitors from Rubus aleaefolius Poir. J Asian Nat Prod Res 4:243-52.
15. Gohar AA, Lahloub MF, Niwa M. (2003). Antibacterial polyphenol from Erodium glaucophyllum. Z Naturforsch 58:670-4.
16. Gowri SS, Vasantha K. (2010). Phytochemical screening and antibacterial activity of Syzygium cumini (L.) (Myrtaceae) leaves extracts. Int J Pharm Tech Res 2:1569-73.
17. Hayman S, Kinoshita JH. (1965). Isolation and properties of lens aldose reductase. J Biol Chem 240:877-82.
18. Helmstadter A. (2007). Antidiabetic drugs used in Europe prior to the discovery of insulin. Pharmazie 62:717-20.
19. Jadhav VM, Kamble SS, Kadam VJ. (2009). Herbal medicine: Syzygium cumini: A review. J Pharm Res 2:1212-19.
20. Khan N, Pathan JK, Harsoliya MS, et al. (2011). Evaluation of analgesic activity of Syzygium cumini (L.) Skeels leaves extract per se & its interactions with diclofenac sodium in thermal and chemical induced pain models. J Pharm Res 4:4129-31.
21. Kumar A, Jayachandran T, Aravindhan P, et al. (2009). Neutral components in the leaves and seeds of Syzygium cumini. Afr J Pharm Pharacol 3:560-1.
22. Lee HS. (2002). Inhibitory activity of Cinnamomum cassia bark-derived component against rat lens aldose reductase. J Pharm Pharm Sci 5: 226-30.
23. Muruganandan S, Srinivasan K, Chandra S, et al. (2001). Antiinflammatory activity of Syzygium cumini bark. Fitoterapia 72: 369-75.
24. Oliveira AC, Endringer DC, Amorim LA, et al. (2005). Effect of the extracts and fractions of Baccharis trimera and Syzygium cumini on glycaemia of diabetic and non-diabetic mice. J Ethnopharmacol 102: 465-9.
25. Omar R, Li L, Yuan T, Seeram NP. (2012). a-Glucosidase inhibitory hydrolyzable tannins from Eugenia jambolana seeds. J Nat Prod 75: 1505-9.
26. Ponnusamy S, Ravindran R, Zinjarde S, et al. (2011). Evaluation of traditional Indian antidiabetic medicinal plants for human pancreatic amylase inhibitory effect in vitro. Evid Based Complement Alternat Med. 2011:515647.
27. Rekha N, Balaji R, Deecaraman M. (2010). Antihyperglycemic and antihyperlipidemic effects of extracts of the pulp of Syzygium cumini and bark of Cinnamon zeylanicum in streptozotocin-induced diabetic rats. J Appl Biosci 28:1718-30.
28. Rodrigues MT, Alves TL, Soares GL, Ritter MR. (2012). Plants used as antidiabetics in popular medicine in Rio Grande do Sul, southern Brazil. J Ethnopharmacol 139:155-63.
29. Sagrawat H, Mann A, Kharya MD. (2006). Pharmacological potential of Eugenia jambolana: A review. Pharmaco-genesis Mag 2:96-105.
30. Saravanan G, Pari L. (2008). Hypoglycaemic and antihyperglycaemic effect of Syzygium cumini bark in streptozotocin-induced diabetic rats. J Pharmacol Toxicol 3:1-10.
31. Sharma B, Viswanath G, Salunke R, Roy P. (2008). Effects of flavonoidrich extract from seeds of Eugenia jambolana (L.) on carbohydrate and lipid metabolism in diabetic mice. Food Chem 110:697-705.
32. Sharma SB, Nasir A, Prabhu KM, Murthy PS. (2006). Antihyperglycemic effect of the fruit-pulp of Eugenia jambolana in experimental diabetes mellitus. J Ethnopharmacol 104:367-73.
33. Simoes-Pires CA, Vargas S, Marston A, et al. (2009). Ellagic acid derivatives from Syzygium cumini stem bark: Investigation of their antiplasmodial activity. Nat Prod Commun 4:1371-6.
34. Srivastava S, Chandra D. (2013). Pharmacological potentials of Syzygium cumini: A review. J Sci Food Agric 93:2084-93.
35. Tanaka JCA, Vidotti GJ, Silva CCD. (2003). A new tormentic acid derivative from Luehea divaricata Mart. (Tiliaceae). J Braz Chem Soc 14:475-8.
36. Weichselbaum TE. (1946). An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma. AJCP 10:40-9.
37. Yamada P, Nemoto M, Shigemori H, et al. (2011). Isolation of 5-(hydroxymethyl)furfural from Lycium chinense and its inhibitory effect on the chemical mediator release by basophilic cells. Planta Med 77:434-40.